Pepcid Complete Tablet, Chewable
NDC Package 70264-034-01
Package Information
Pepcid Complete (famotidine, calcium carbonate, and magnesium hydroxide) tablets is adults and children 12 years and over: do not swallow tablet whole: chew completelyto relieve symptoms, chew 1 tablet before swallowing do not use more than 2 chewable tablets in 24 hourschildren under 12 years: ask a doctor. This formulation utilizes a tablet, chewable delivery system. Marketed by R J General Corporation, this product is identified by NDC 70264-034 and is authorized under FDA application NDA020958.
Identification & Billing
- RxCUI: 283641 - famotidine 10 MG / calcium carbonate 800 MG / magnesium hydroxide 165 MG Chewable Tablet
- RxCUI: 283641 - calcium carbonate 800 MG / famotidine 10 MG / magnesium hydroxide 165 MG Chewable Tablet
- RxCUI: 283641 - calcium carbonate 800 MG / famotidine 10 MG / milk of magnesia 165 MG Chewable Tablet
- RxCUI: 688892 - Pepcid Complete Dual Action 10 MG / 800 MG (Ca 320 MG) / 165 MG Chewable Tablet
- RxCUI: 688892 - calcium carbonate 800 MG / famotidine 10 MG / magnesium hydroxide 165 MG Chewable Tablet [Pepcid Complete]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 70264 - R J General Corporation
- 70264-034 - Pepcid Complete
- 70264-034-01 - 50 TABLET, CHEWABLE in 1 CARTON
- 70264-034 - Pepcid Complete
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 70264-034-01 identifies a specific commercial package of 50 tablet, chewable in 1 carton of Pepcid Complete, a human over the counter drug labeled by R J General Corporation. This tablet, chewable is formulated for oral use and contains calcium carbonate; famotidine; magnesium hydroxide as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by R J General Corporation on January 09, 2022. The current certification is valid through December 31, 2026.
How is this R J General Corporation product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 70264003401. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.